Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARP02
- Development stage
- Unknown
- Lead developer
- Nanjing Aoluo Biotechnology
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ARP02 is an investigational mRNA-based therapeutic vaccine developed by Wuhan Infectious Diseases Hospital (Wuhan Jinyintan Hospital) for the treatment of recurrent genital herpes caused by herpes simplex virus type 2 (HSV-2). The vaccine is designed to encode specific HSV-2 antigens, which, upon administration, stimulate the host's immune system to mount both humoral and cellular responses. The primary goal of the therapy is to reduce the frequency and severity of symptomatic outbreaks and viral shedding in individuals with established HSV-2 infections. ARP02 is currently being evaluated in exploratory clinical trials to assess its safety, tolerability, and immunogenicity.
- Other names
- ARP02 HSV-2 mRNA vaccineARP-02 HSV-2 mRNA vaccineARP 02 HSV-2 mRNA vaccine
02
Targets
PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on ARP02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARP02.